HCP
Dymista Menu
HCP
 

Dymista®: More patients are symptom-free than with FP or AZE  

Dymista®: Impact of treatment by disease severity  

Twice as effective for treating all allergic rhinitis symptoms

left left
right right
Dymista®: More patients are symptom-free than with FP or AZE  
Dymista®: Impact of treatment by disease severity  
Twice as effective for treating all allergic rhinitis symptoms

 

Adapted from Bousquet et al A new efficacy parameter (complete or near complete symptom relief) in AR management : results with a new therapy MP29-02*. Poster presented at Symposium on Experimental Rhinology and Immunology of the Nose (SERIN), Leuven (Belgium) 21-23 March 2013.

1 out of 6 Dymista® patients achieve complete or near to complete symptom relief by day 14. 

*Dymista®

Adapted from Scadding et al. A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity. Abstract presented at the Symposium on Experimental Rhinology and Immunology of the Nose (SERIN), Leuven (Belgium) 21-23 March 2013.

AR: allergic rhinitis; FP: fluticasone propionate; AZE: azelastine; rTNSS: reflective Total Nasal Symptom Score. Results expressed as LS mean change from baseline (delta placebo) with 95% CI.

Dymista® provides benefits for all patients regardless of the severity of their symptoms. Allergic rhinitis patients treated with Dymista® experience significantly greater overall relief from their nasal symptoms than either intranasal fluticasone propionate or azelastine hydrochloride,  even those with more severe symptoms who are currently difficult to treat. 

 

*Dymista®

In a double-blind, placebo-controlled, 14 day, parallel-group trial, 610 patients (≥12 years old) with moderate-to-severe SAR were randomised to either Dymista®, commercially-available azelastine (AZE) or fluticasone propionate (FP) nasal sprays and placebo (all given as 1 spray/nostril bid (total daily doses: AZE = 548µg: FP = 200µg) Adapted from Price et al. A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex. Poster presented at the Symposium on Experimental Rhinology and Immunology of the Nose (SERIN), Leuven (Belgium) 21-23 March 2013.

rT7SS: Total of 7 symptom scores (All nasal plus all ocular symptoms); FP: fluticasone propionate (n=151) AZE: azelastine (n=153); Dymista® (n= 153). Results expressed as LS mean change from baseline (delta placebo) with 95% CI. 

Dymista® is a major advancement in the treatment of allergic rhinitis since it is twice as effective as current firstline therapy (fluticasone propionate or azelastine nasal sprays)  in treating the entire rhinitis symptom complex, providing uniform relief from both nasal and ocular symptoms.

*Dymista®

UK/DYM/14/0070(1) Date of Prep: February 2017

Login

Log in

CloseClose

Sign in to Dymista

Don't have a Dymista account?

The website you are trying to access is designed for UK Healthcare Professionals only - the content is not designed for the general public.


Are you a UK Healthcare Professional?

Yes No
Why do I need to answer this?

No, I am not a HCP

Sorry, you do not have the authorization to enter this webpage.

Go back Go back
close-icon